The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats
- PMID: 18292809
- PMCID: PMC2248328
- DOI: 10.1172/JCI33160
The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats
Abstract
Hemodynamic overload in the heart can trigger maladaptive hypertrophy of cardiomyocytes. A key signaling event in this process is nuclear acetylation by histone deacetylases and p300, an intrinsic histone acetyltransferase (HAT). It has been previously shown that curcumin, a polyphenol responsible for the yellow color of the spice turmeric, possesses HAT inhibitory activity with specificity for the p300/CREB-binding protein. We found that curcumin inhibited the hypertrophy-induced acetylation and DNA-binding abilities of GATA4, a hypertrophy-responsive transcription factor, in rat cardiomyocytes. Curcumin also disrupted the p300/GATA4 complex and repressed agonist- and p300-induced hypertrophic responses in these cells. Both the acetylated form of GATA4 and the relative levels of the p300/GATA4 complex markedly increased in rat hypertensive hearts in vivo. The effects of curcumin were examined in vivo in 2 different heart failure models: hypertensive heart disease in salt-sensitive Dahl rats and surgically induced myocardial infarction in rats. In both models, curcumin prevented deterioration of systolic function and heart failure-induced increases in both myocardial wall thickness and diameter. From these results, we conclude that inhibition of p300 HAT activity by the nontoxic dietary compound curcumin may provide a novel therapeutic strategy for heart failure in humans.
Figures
Comment in
-
Currying favor for the heart.J Clin Invest. 2008 Mar;118(3):850-2. doi: 10.1172/JCI34650. J Clin Invest. 2008. PMID: 18292806 Free PMC article.
References
-
- Ho K.K., Levy D., Kannel W.B., Pinsky J.L. The epidemiology of heart failure: the Framingham study. J. Am. Coll. Cardiol. 1993;22:6–13. - PubMed
-
- Dominguez L.J., Parrinello G., Amato P., Licata G. Trends of congestive heart failure epidemiology: contrast with clinical trial results. Cardiologia. 1999;44:801–808. - PubMed
-
- Dorn G.W., II, Robbins J., Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 2003;92:1171–1175. - PubMed
-
- Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003;65:45–79. - PubMed
-
- Chien K.R. Stress pathways and heart failure. Cell. 1999;98:555–558. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
